GT Biopharma Analyst Ratings
GT Biopharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 1685.71% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/07/2023 | 614.29% | EF Hutton | → $2 | Reiterates | Hold → Hold |
| 06/05/2023 | 1685.71% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 05/17/2023 | 1685.71% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 05/16/2023 | 614.29% | EF Hutton | → $2 | Reiterates | Hold → Hold |
| 04/03/2023 | 1685.71% | HC Wainwright & Co. | → $5 | Reiterates | → Buy |
| 03/31/2023 | 614.29% | EF Hutton | → $2 | Reiterates | → Hold |
| 01/05/2023 | 614.29% | EF Hutton | → $2 | Initiates Coverage On | → Hold |
| 09/13/2022 | 1685.71% | HC Wainwright & Co. | $25 → $5 | Maintains | Buy |
| 05/24/2021 | 8828.57% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 04/13/2021 | 7400% | B. Riley Securities | → $21 | Initiates Coverage On | → Buy |
| 03/17/2021 | 8828.57% | Roth Capital | → $25 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/08/2023 | 1685.71% | HC Wainwright & Co. | → 5 美元 | 重申 | 購買 → 購買 |
| 08/07/2023 | 614.29% | EF Hutton | → 2 美元 | 重申 | 按住 → 按住 |
| 06/05/2023 | 1685.71% | HC Wainwright & Co. | → 5 美元 | 重申 | 購買 → 購買 |
| 05/17/2023 | 1685.71% | HC Wainwright & Co. | → 5 美元 | 重申 | 購買 → 購買 |
| 05/16/2023 | 614.29% | EF Hutton | → 2 美元 | 重申 | 按住 → 按住 |
| 04/03/2023 | 1685.71% | HC Wainwright & Co. | → 5 美元 | 重申 | → 購買 |
| 03/31/2023 | 614.29% | EF Hutton | → 2 美元 | 重申 | → 按住 |
| 01/05/2023 | 614.29% | EF Hutton | → 2 美元 | 啓動保障 | → 按住 |
| 09/13/2022 | 1685.71% | HC Wainwright & Co. | 25 美元 → 5 美元 | 維持 | 購買 |
| 2021 年 5 月 24 日 | 8828.57% | HC Wainwright & Co. | → 25 美元 | 啓動保障 | → 購買 |
| 04/13/2021 | 7400% | B. 萊利證券 | → 21 美元 | 啓動保障 | → 購買 |
| 03/17/2021 | 8828.57% | 羅斯資本 | → 25 美元 | 啓動保障 | → 購買 |
What is the target price for GT Biopharma (GTBP)?
GT Biopharma（GTBP）的目標價格是多少？
The latest price target for GT Biopharma (NASDAQ: GTBP) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $5.00 expecting GTBP to rise to within 12 months (a possible 1685.71% upside). 9 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年8月8日公佈了GT Biopharma（納斯達克股票代碼：GTBP）的最新目標股價。該分析公司將目標股價設定爲5.00美元，預計GTBP將在12個月內上漲（可能上漲1685.71％）。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for GT Biopharma (GTBP)?
GT Biopharma（GTBP）的最新分析師評級是多少？
The latest analyst rating for GT Biopharma (NASDAQ: GTBP) was provided by HC Wainwright & Co., and GT Biopharma reiterated their buy rating.
GT Biopharma（納斯達克股票代碼：GTBP）的最新分析師評級由HC Wainwright & Co. 提供，GT Biopharma重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for GT Biopharma (GTBP)?
GT Biopharma（GTBP）的下一個分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GT Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GT Biopharma was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與GT Biopharma的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。GT Biopharma的最後一次評級是在2023年8月8日提交的，因此您應該預計下一個評級將在2024年8月8日左右公佈。
Is the Analyst Rating GT Biopharma (GTBP) correct?
分析師評級GT Biopharma（GTBP）是否正確？
While ratings are subjective and will change, the latest GT Biopharma (GTBP) rating was a reiterated with a price target of $0.00 to $5.00. The current price GT Biopharma (GTBP) is trading at is $0.28, which is within the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但GT Biopharma（GTBP）的最新評級得到了重申，目標股價爲0.00美元至5.00美元。GT Biopharma（GTBP）目前的交易價格爲0.28美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。